At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 6:41:51 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 1 | 2 | 2 |
| Avg. Estimate | 0.04 | 0.03 | 0.19 | 0.34 |
| Low Estimate | 0.04 | 0.03 | 0.18 | 0.26 |
| High Estimate | 0.04 | 0.03 | 0.2 | 0.41 |
| Year Ago EPS | 0 | -0.07 | -- | 0.19 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 2 | 5 | 5 |
| Avg. Estimate | 71.71M | 68.05M | 276.94M | 331.89M |
| Low Estimate | 68.47M | 68M | 273.68M | 321.29M |
| High Estimate | 74.1M | 68.09M | 279.3M | 345.6M |
| Year Ago Sales | 55.6M | 50.79M | 232.28M | 276.94M |
| Sales Growth (year/est) | 28.99% | 33.98% | 19.23% | 19.84% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.01 | -0.03 | 0.07 | 0.12 |
| EPS Actual | 0 | -0.07 | 0.08 | 0.12 |
| Difference | -0.01 | -0.05 | 0.01 | 0 |
| Surprise % | -100.00% | -180.00% | 14.29% | 4.35% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.04 | 0.03 | 0.19 | 0.34 |
| 7 Days Ago | 0.03 | 0.02 | 0.17 | 0.3 |
| 30 Days Ago | 0.01 | 0.02 | 0.17 | 0.31 |
| 60 Days Ago | 0.01 | 0.02 | 0.17 | 0.31 |
| 90 Days Ago | 0.01 | 0.02 | 0.17 | 0.31 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| DVAX | 0.00% | 142.86% | -- | 76.32% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/15/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 8/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/14/2024 |
Related Tickers
PCRX Pacira BioSciences, Inc.
19.86
+0.30%
LFCR Lifecore Biomedical, Inc.
7.61
+0.40%
EBS Emergent BioSolutions Inc.
8.48
-2.42%
EOLS Evolus, Inc.
11.51
-0.60%
KMDA Kamada Ltd.
5.87
+1.38%
IRWD Ironwood Pharmaceuticals, Inc.
3.5300
-0.84%
AVDL Avadel Pharmaceuticals plc
10.39
-2.07%
ANIK Anika Therapeutics, Inc.
17.16
-0.98%
ASRT Assertio Holdings, Inc.
0.9200
-3.32%
ETON Eton Pharmaceuticals, Inc.
12.35
+1.56%